Agios Pharmaceuticals (NASDAQ:AGIO) Insider Tsveta Milanova Sells 3,262 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 3,262 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the sale, the insider owned 46,829 shares in the company, valued at approximately $1,625,434.59. This represents a 6.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ AGIO opened at $34.80 on Tuesday. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -4.89 and a beta of 0.79. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The company’s 50-day moving average price is $29.00 and its 200 day moving average price is $32.12.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AGIO. Leerink Partners raised their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Truist Financial raised their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. The Goldman Sachs Group raised their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Finally, Bank of America raised their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $42.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. lifted its stake in shares of Agios Pharmaceuticals by 31.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 21,071 shares of the biopharmaceutical company’s stock worth $574,000 after purchasing an additional 5,033 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $183,000. Seven Fleet Capital Management LP acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $864,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $25,000. Finally, Invesco Ltd. lifted its stake in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock worth $3,881,000 after purchasing an additional 15,604 shares in the last quarter.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (maintaining a “neutral” rating), signaling modest analyst upside and providing some support for the share price. Article Link
• Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29, 2026 — a standard corporate update that can trigger short-term moves around results but is informational until the release. Press Release
• Neutral Sentiment: Insider sale — Tsveta Milanova sold 3,262 shares at ~$34.71 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting; trade reduces her holdings ~6.5% but was routine and pre-planned. SEC Filing
• Neutral Sentiment: Insider sale — CFO Cecilia Jones sold 3,141 shares at ~$34.71 via a Rule 10b5-1 plan to cover taxes on vested awards; holding reduced ~5.4%. Investors typically view such planned tax-related sales as neutral. SEC Filing
• Neutral Sentiment: Insider sale — Sarah Gheuens sold 2,940 shares at ~$34.71 under a pre-arranged plan to cover tax withholding; position decreased ~3.5%. SEC Filing
• Neutral Sentiment: Insider sale — James William Burns sold 3,280 shares at ~$34.71 via a Rule 10b5-1 plan to cover tax obligations; holdings down ~6.2%. SEC Filing

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.